Article info
PDFTherapeutics
Original article
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
- Correspondence to Dr Behzad Najafian, Department of Pathology, University of Washington, Box 356100, 1959 NE Pacific St, Seattle, WA 98195, USA; najafian{at}uw.edu
Citation
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
Publication history
- Received May 19, 2017
- Revised June 15, 2017
- Accepted June 19, 2017
- First published July 29, 2017.
Online issue publication
October 23, 2017
Article Versions
- Previous version (29 July 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/